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Accepted 23 July 2019; Published online 27 July 2019AbstractObjectives: Minimal clinically important differences (MCIDs) are used as fixed numbers in the interpretation of clinical trials. Little is
known about its dynamics. This study aims to explore the impact of baseline score, study setting, and patient characteristics on health status
MCIDs in chronic obstructive pulmonary disease (COPD).
Study Design and Setting: Baseline and follow-up data on the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ),
and St. George’s Respiratory Questionnaire (SGRQ) were retrospectively analyzed from pulmonary rehabilitation (PR) and routine clinical
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50 H. Alma et al. / Journal of Clinical Epidemiology 116 (2019) 49e61for Obstructive Lung Disease (GOLD) classification, comorbidities, and baseline health status.
Results: In total, 658 patients were included with 2,299 change score measurements. MCID estimates for improvement and deteriora-
tion ranged for all subgroups 0.50e6.30 (CAT), 0.10e0.84 (CCQ), and 0.33e12.86 (SGRQ). Larger MCID estimates for improvement and
smaller ones for deterioration were noted in patients with worse baseline health status, females, elderly, GOLD I/II patients, and patients
with less comorbidities. Estimates from PR were larger.
Conclusion: Baseline health status and setting affected MCID estimates of COPD health status questionnaires. Patterns were observed
for gender, age, spirometry classification, and comorbidity levels. These outcomes would advocate the need for tailored MCIDs.  2019
The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
nses/by-nc-nd/4.0/).Keywords: Chronic obstructive pulmonary disease (COPD); Health status; Minimal clinically important difference (MCID); COPD Assessment Test (CAT);
Clinical COPD Questionnaire (CCQ); St. George’s Respiratory Questionnaire (SGRQ)1. Background
Health status measurement has been defined as ‘‘a stan-
dardized way of quantifying the impact of disease on a pa-
tient’s life, health, and well-being’’ [1]. It provides
important information about the burden of diseased
especially in patients with chronic obstructive pulmonary
disease (COPD)dbecause physiologic measures like
spirometry alone do not measure the full aspect of this
chronic disorder [1e7]. Many factors may impact health
status in COPD, including the number and severity of exac-
erbations [8e10]; the disease severity defined according to
the Global initiative for Obstructive Lung Disease (GOLD)
spirometry classification [5,9e12]; the patient’s gender and
age [5,8e10,13e15]; and the amount of comorbidities [12].
Moreover, the baseline score may also be predictive of
(worsening) health status [11,14].
Health status is, in addition to spirometry, an obligatory
endpoint in evaluating treatment outcomes of clinical trials
[16]. An intervention or therapy should result in meaningful
clinical changes using outcomes that are relevant for pa-
tients themselves [16e18]. A parameter to interpret and
define important change in health status is the minimal clin-
ically important difference (MCID). It has been defined as
‘‘the smallest difference in score in the domain of interest
which patients perceive as beneficial and which would
mandate, in absence of troublesome side effects and exces-
sive costs, a change in patient management’’ [19]. Like
health status, MCIDs may also be influenced by multiple
patient- and disease-related factors. Previous publications
speculated that MCIDs for quality of life tools may be
affected by patient characteristics such as age, gender,
and education; the number of comorbidities; initial baseline
condition of the patient; and pathologic characteristics of
the disorder including disease severity [16,17,20e39]. It re-
mains, however, unclear whether different MCIDs should
be used in practice depending on disease severity, patient
characteristics, and baseline health state.
Various studies have discussed the MCID of COPD
health status tools [40], including the recommended ques-
tionnaires COPD Assessment Test (CAT), Clinical COPDQuestionnaire (CCQ), and the St. George’s Respiratory
Questionnaire (SGRQ) [2,41,42]. The MCIDs were deter-
mined as a rather fixed range of two to three points on
the CAT [40,43e49], 0.40e0.50 on the CCQ
[40,43,44,48e52], and four up to seven points on the
SGRQ [40,43,44,53e57]. However, little is known about
the dynamics of these MCIDs and the impact of different
(disease) characteristics of patients on it. The present study
aims to explore patient- and disease-related influences upon
the MCID estimates for these recommended instruments in
patients with COPD from different settings, in this case pul-
monary rehabilitation (PR) and routine clinical practice
(RCP).2. Methods
2.1. Study subjects and design
Data from patients with COPD in two studies were retro-
spectively analyzed: (1) the 3-week full-day inpatient
Routine Inspiratory Muscle Training within COPD Reha-
bilitation (RIMTCORE ) real-life randomized controlled
trial during PR in Klinik Bad Reichenhall (Center for Reha-
bilitation, Pulmonology, and Orthopedics) in Germany
[43,58] and (2) an observational trial (MCID study) aimed
primarily at measuring health status changes in Dutch pri-
mary and secondary RCP [59].
2.2. Data collection
Patient descriptive characteristics and postbronchodila-
tor spirometry were collected at baseline. CAT (no recall),
CCQ (1 week recall), and SGRQ (1 month recall) were
scored at baseline and during follow-up as study outcomes.
In the RIMTCORE trial, follow-up questionnaires were
scored at discharge (3 weeks) and at 3/6/9/12 months
(Fig. 1). In RCP, respective health status questionnaires
were scored at baseline and after 3/6/12 months. The
CAT contains eight items and a total maximum score of
40 (maximum impairment) [60]. The CCQ consists of ten
items and a total maximum score of six (maximum
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Key findings
 Larger minimal clinically important difference
(MCID) estimates for improvement and smaller
ones for deterioration on chronic obstructive pul-
monary disease (COPD) health status tools were
observed in patients with worse baseline health sta-
tus, females, elderly, Global initiative for Obstruc-
tive Lung Disease I/II patients, and in patients with
less comorbidities.
 MCID estimates for COPD health status tools were
generally larger for both improvement and deterio-
ration during a pulmonary rehabilitation interven-
tion compared with routine clinical practice
without intervention.
What this adds to what was known?
 This is the first study to explore the dynamics of
the MCID of COPD health status tools by inte-
grating the influence of baseline health status, pa-
tient characteristics, disease severity, and study
setting.
What is the implication and what should change
now?
 Currently, fixed MCIDs of COPD health status
tools are used for the interpretation of clinical trial
results; however, the present study would advocate
the need for clustered or even tailored MCIDs to
enable a more individual evaluation of change
scores.
impairment) [61]. The SGRQ contains 50 items and a total
score of 100 (maximum impairment) [62]. A 15-point
Global Rating of Change (GRC) scale was scored in both
studies for each follow-up moment. It required patients to
assess their experienced change in COPD health status
compared with baseline. Answers were scored on a scale
from minus seven (very much worse) to plus seven (very
much better) with zero equaling no change [63].
2.3. Study methods to determine MCIDs
Health status change scores were calculated as the dif-
ference between follow-up and baseline scores. Negative
change represented improvement, and positive change rep-
resented deterioration. MCID estimates were calculated us-
ing anchor- and distribution-based methods. The anchor-
based approach required patients to be categorized accord-
ing to their GRC score. Scores of 0 and 61 on the GRC
scale indicated no change; scores of 62 and 63 repre-
sented minimal improvement/deterioration; scores of 64
H. Alma et al. / Journal of Cliniand 65 were considered moderate improvement/deteriora-
tion; and scores of 66 and 67 indicated large improve-
ment/deterioration [63]. The mean health status change
score of the minimal change group according to the GRC
represented the MCID estimate, assuming normality of dis-
tribution. In addition, the GRC score for minimally
improved and deteriorated was used as a cutpoint for
dichotomization in the receiver operating characteristics
(ROC) curve analysis [64]. Finally, the distribution-based
approach included the half standard deviation (0.5SD) of
the health status change score [65]. Study methods were
performed separately for improvement and deterioration.
MCID estimates were evaluated and statistically tested be-
tween subgroups for study settings (PR and RCP); males
and females; low and high age (median as cutpoint); low
(GOLD IeII) vs. high (GOLD IIIeIV) COPD disease
severity; low and high levels of comorbidities on the Charl-
son Index (median as cutpoint); and better and worse base-
line health status (median as cutpoint).2.4. Data analysis and statistics
SPSS, version 25.0, (IBM, Chicago) was used for data
analysis. Baseline, follow-up, and change scores were as-
sessed. Frequencies with percentages, mean with SD, or
median with interquartile range (IQR) were determined de-
pending on the variable characteristics. Normality of distri-
bution was assessed for continuous variables using
histograms, and skewness and kurtosis with values between
1 and þ1 indicative for normality. Baseline scores be-
tween both data sets were tested for a difference using in-
dependent t-tests, Mann Whitney U-tests, or chi-square
tests depending on type of data and whether assumptions
were met. Health status and GRC scores were assessed
for floor and ceiling effects, defined as over 15% of patients
scoring in the lowest and highest 10% of the maximum
scale range [66]. Baseline and follow-up health status
scores were tested for significance of change using paired
t-tests or Wilcoxon-signed rank tests. Pair-wise deletion
was applied. The false discovery rate (FDR) due to multiple
testing was controlled for by BenjaminieHochberg’s step-
up procedure to maintain an overall two-sided type I error
rate of 5% [67]. Adjusted P-values are reported. Intraclass
correlation coefficients (ICCs) of the health status change
scores were determined to assess dependency of data. The
impact of regression to the mean was determined as
100(1r1/2) with r reflecting the ICC.
Correlations were assessed between the GRC and health
status change scores using Pearson coefficients assuming
normality of distribution and the GRC to be a continuous
variable. Correlations were required 0.30 [68]. Patients
were categorized per GRC class. Significance of change
within each GRC category was tested using paired t-tests
or Wilcoxon-signed rank tests. ANOVA was performed to
statistically test for significant differences between GRC
categories and to determine the mean change scores
Fig. 1. Study methods of the MCID (subgroup) analysis. Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD,
chronic obstructive pulmonary disease; GRC, Global Rating of Change; SGRQ, St. George’s Respiratory Questionnaire; T0, baseline; T1, follow-
up at 3 weeks; T2, follow-up at 3 months; T3, follow-up at 6 months; T4, follow-up at 9 months; T5, follow-up at 12 months.
52 H. Alma et al. / Journal of Clinical Epidemiology 116 (2019) 49e61including confidence interval per class. The mean change
scores of the minimally improved and/or deteriorated group
of patients represented the MCID estimates. Furthermore,
ROC curves used a GRC score of 62 as cutoff values to
dichotomize the data set to differentiate between important
and unimportant change [24,34,38]. The area under the
curve (AUC) was calculated, and the optimal combinationTable 1. Patient characteristics and health status scores
Variable Pulmonary rehabilitation
Number of patients (N ) 451
Age (years)a 57.87 6 6.56
Gender (male)b 293 (65.0)
FEV1%preda 50.40 6 15.11
GOLD Ib -
GOLD II 227 (50.3)
GOLD III 176 (39.0)
GOLD IV 48 (10.6)
Smoking pack yearsa 40.00 (30.00e50.00)
Baseline CATa 20.23 6 7.33
Baseline CCQ Totala 2.86 6 1.17
Baseline SGRQ Totala 50.69 6 17.33
Baseline mMRCa 2 (2e4)
D CAT 12 monthsa 0.89 6 7.01
D CCQ Total 12 monthsa 0.16 6 1.08
D SGRQ Total 12 monthsa 3.94 6 15.38
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Quest
Forced Expiratory Volume in one second % predicted; GOLD, Global initia
Research Council Dyspnea Scale; N, number of patients; SGRQ, St. George
a Data expressed as mean 6 standard deviation or median (interquartil
b Data expressed as frequencies (% of total).
c
Significance level P! 0.05. All listed P-values were corrected for multiplof sensitivity and specificity was selected as MCID esti-
mate (lowest sum of [1  sensitivity] and [1  specificity])
[64].
Independent t-tests were used to determine significance
of the difference between MCID estimates for the various
subgroups. These subgroups were determined for nominal
values as the respective categories. For the continuousRoutine clinical practice Significance
207
66.69 6 7.91 P ! 0.001c
121 (58.5) P 5 0.507
57.06 6 21.96 P 5 0.012c




37.5 (22.50e51.25) P 5 0.108
18.32 6 7.22 P 5 0.003c
2.12 6 1.02 P ! 0.001c
42.88 6 19.16 P ! 0.001c
1 (1e2) P ! 0.001c
0.14 6 4.92 P 5 0.224
0.02 6 0.69 P 5 0.077
0.87 6 11.55 P ! 0.001c
ionnaire; COPD, chronic obstructive pulmonary disease; FEV1%pred,
tive for Chronic Obstructive Lung Disease; mMRC, modified Medical
’s Respiratory Questionnaire.
e range).
icity using the BenjaminieHochberg method.
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subgroups [24,28,34,35,69]. To control for the possible
impact of the baseline level, relative MCIDs were also
calculated as a percentage of change from baseline
[21,29,36]. Finally, 0.5SDs were determined for all patients
and the respective subgroups.
Multiple linear regression modeling was applied to
quantify the impact of the various factors (baseline health
status, gender, age, GOLD classification, and study setting)
on the MCID estimates, including the analysis of possible
interaction terms.3. Results
3.1. Baseline characteristics
This retrospective analysis included 451 patients from
PR of whom 309 patients completed follow-up and 207 pa-
tients from RCP of whom 177 completed follow-up
(Table 1).3.2. Global Rating of Change
Correlations between the GRC and health status change
scores (n 5 2,299) were 0.38 (CAT), 0.45 (CCQ), and
0.52 (SGRQ). The scores on the GRC differed signifi-
cantly between both study settings (P ! 0.001) (Fig. 2).Fig. 2. Distribution of the GRC scores during PR and RCP. The blue bars (left
The green bars (right half) represent the observed frequencies per GRC cate
study settings (P ! 0.001). Abbreviations: GRC, Global Rating of Change;ANOVA tests between GRC groups were all significant
(P ! 0.001).
3.3. Study setting
Mean MCID estimates were for all patients for improve-
ment and deterioration 2.82 vs. 2.66 (CAT), 0.48 vs.
0.43 (CCQ), and 8.30 vs. 5.95 (SGRQ), respectively
(Table 2). Estimates were larger during PR than RCP for
improvement on the CCQ (0.49 vs. 0.40, P 5 0.687)
and SGRQ (8.71 vs.3.04, P5 0.020), and for deteriora-
tion on the CAT (3.44 vs. 1.50, P 5 0.023), CCQ (0.51 vs.
0.30, P 5 0.090), and SGRQ (6.11 vs. 5.69, P 5 0.825)
(Table 2). ROC curves demonstrated a similar pattern,
although estimates for deterioration were overall smaller
than for improvement (Table 3). The 0.5SD estimates were
also larger during PR than RCP (CAT 3 vs. 2 points; CCQ
0.5 vs. 0.3 points; and SGRQ 6e7 vs. 4e5 points)
(Table 4). ICCs of the health status change scores and percent
regression to the mean ranged 0.59e0.68 (17.66e23.12%)
for PR and 0.75e0.89 (5.50e13.69%) for RCP.
3.4. Baseline health status
Better and worse baseline levels were grouped according
to the median (CAT 20, CCQ 2.60, and SGRQ 49.09). MCID
estimates for improvement were significantly smaller and for
deterioration significantly larger in patients with a lowerhalf) represent the observed frequencies per GRC category during PR.
gory during RCP. The GRC scores differed significantly between both
PR, pulmonary rehabilitation; RCP, routine clinical practice.
Table 2. Anchor-based MCID estimates for CAT, CCQ, and SGRQ using the mean change method
Patients N CAT CCQ SGRQ N CAT CCQ SGRQ
Improvement Improvement Improvement Deterioration Deterioration Deterioration




















































































P < 0.001a P < 0.001a P < 0.001a 272
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Significance 611 P = 0.544 P = 0.028a P = 0.655 272 P = 0.872 P = 0.011a P = 0.193


























Significance 611 P = 0.413 P = 0.099 P = 0.635 272 P = 0.985 P = 0.370 P = 0.916

























































Significance 44 P = 0.778 P = 0.888 P = 0.748 109 P = 0.642 P = 0.941 P = 0.187
Abbreviations: 95% CI, 95% confidence interval; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive
pulmonary disease; GOLD, Global initiative for Chronic Obstructive Lung Disease; N, number of patients; PR, pulmonary rehabilitation; RCP,
routine clinical practice; SGRQ, St. George’s Respiratory Questionnaire.
Data presented as mean change scores (95% CI).
Scores marked in lighter green represent smaller MCID estimates, whereas darker green represent larger MCID estimates.
aSignificance level P ! 0.05 using independent t-tests. All listed P-values were corrected for multiplicity using the BenjaminieHochberg
method.
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RCP (P! 0.001; Table 2; Fig. 3; Supplementary Table 1).
Improvement thresholds for lower (meaning better) baseline
compared with higher (meaning worse) baseline were for
CAT 0.67 vs. 4.78, for CCQ 0.13 vs. 0.82, and forSGRQ 4.66 vs. 12.18. Thresholds for deterioration were
for CAT 6.30 vs. 0.92, for CCQ 0.84 vs. 0.21, and for SGRQ
12.86 vs. 2.15. ROC curves confirmed the pattern, although
differences were less extreme between baseline severity
groups (Table 3). The 0.5SD method did not show large
Table 3. Anchor-based MCID estimates for CAT, CCQ, and SGRQ using ROC curves
Patients CAT CCQ SGRQ CAT CCQ SGRQ
Improvement Improvement Improvement Deterioration Deterioration Deterioration
















































































































































































Abbreviations: AUC, area under the curve; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmo-
nary disease; GOLD, Global initiative for Chronic Obstructive Lung Disease; N, number of patients with important change; PR, pulmonary rehabil-
itation; RCP, routine clinical practice; ROC, receiver operating characteristics; SGRQ, St. George’s Respiratory Questionnaire.
Data presented as MCID estimates from the ROC curves including the AUC.
Scores marked in lighter green represent smaller MCID estimates, whereas darker green represent larger MCID estimates.
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Table 2). Relative MCID estimates compared with baseline
were for improvement and deterioration 7.42% and
þ19.25% (CAT); 11.29% and þ22.65% (CCQ), and
14.31% and þ18.84% (SGRQ), respectively. Their confi-
dence intervals included for improvement 10% and for
deterioration þ20%. Percentage regression to the mean for
low-baseline (meaning better) patients ranged from 31.66
to 37.55% (PR: 29.36e37.55%; RCP: 38.36e48.52%), and
from 36.91 to 39.67% (PR: 38.52e40.84%; RCP:
28.80e34.20%) for high-baseline (meaning worse) patients.3.5. Other variables
Compared with males, females noted larger MCID esti-
mates for improvement (CAT 3.23 vs. 2.56, P 5 0.544;
CCQ 0.63 vs. 0.38, P5 0.028; SGRQ 8.74 vs. 8.01,
P 5 0.655) and smaller ones for deterioration (CAT 2.51
vs. 2.74, P 5 0.872; CCQ 0.23 vs. 0.54, P 5 0.011; SGRQ
4.43 vs. 6.79, P 5 0.193) during both PR and RCP
(Table 2, Supplementary Table 1). ROC curves partly
confirmed this, yet MCID estimates for deterioration were
smaller than for improvement (Table 3). The 0.5SD
Table 4. Distribution-based MCID estimates for CAT, CCQ, and SGRQ using the half standard deviation
Patients CAT CCQ SGRQ CAT CCQ SGRQ
Improved Improved Improved Deteriorated Deteriorated Deteriorated
All patients −2.99 −0.46 −6.43 2.79 0.42 5.65
PR patients −3.04 −0.47 −6.54 3.10 0.47 6.28
RCP patients −2.24 −0.30 −4.08 2.11 0.30 4.54
Better baseline health status −2.81 −0.41 −6.17 2.88 0.39 5.46
Worse baseline health status −2.81 −0.44 −6.12 2.28 0.39 4.80
Males −3.02 −0.44 −6.30 2.52 0.43 6.12
Females −2.94 −0.48 −6.63 3.23 0.37 4.62
Age Low −2.97 −0.47 −6.07 2.71 0.48 6.26
Age High −3.01 −0.45 −6.89 2.84 0.36 5.07
GOLD I-II −3.15 −0.44 −6.16 2.61 0.45 5.41
GOLD III-IV −2.82 −0.49 −6.64 2.95 0.38 5.85
Comorbidities Low −2.40 −0.31 −4.40 2.13 0.28 4.51
Comorbidities High −1.79 −0.28 −3.18 2.09 0.33 4.47
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; GOLD, Global
initiative for Chronic Obstructive Lung Disease; PR, pulmonary rehabilitation; RCP, routine clinical practice; SGRQ, St. George’s Respiratory Ques-
tionnaire.
Data presented as half standard deviation MCID estimates of the health status change score.
Scores marked in lighter green represent smaller MCID estimates, whereas darker green represent larger MCID estimates.
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on the CAT and SGRQ (Table 4, Supplementary Table 2).
Younger patients had, compared with older patients (me-
dian 60 years), smaller MCID estimates for improvement
(CAT 2.49 vs. 3.25, P 5 0.413; CCQ 0.41 vs. 0.57,
P 5 0.099; SGRQ 7.98 vs. 8.71, P 5 0.635), but larger
estimates for deterioration (CAT 3.18 vs. 2.19, P 5 0.985;
CCQ 0.50 vs. 0.37, P 5 0.370; SGRQ 5.88 vs. 6.02,
P 5 0.916) (Table 2). This pattern was different in RCP
(Supplementary Table 1). ROCcurves confirmed this pattern,
except for deterioration on the CAT (Table 3). The 0.5SD
estimates were consistent between both age groups (Table 4).
GOLD IIIeIV patients scored smaller MCID estimates
for improvement (CAT 2.63 vs. 3.01, P 5 0.661; CCQ
0.44 vs. 0.53, P 5 0.425; and SGRQ 6.64 vs. 9.90,
P 5 0.062) and larger ones for deterioration (CAT 2.97 vs.
2.35, P 5 0.670; SGRQ 7.10 vs. 4.86, P 5 0.224)
(Table 2). The pattern was different for improvement in
RCP (Supplementary Table 1). ROC curves confirmed the
pattern for improvement (Table 3). The 0.5SD estimates
were consistent between both GOLD groups (Table 4).
3.6. Linear multiple regression analysis and interaction
Supplementary Table 3 demonstrates the best regression
models for the MCID estimates of the CAT, CCQ, and SGRQ.
Baseline health status and study setting were frequent, signif-
icant, and independent factors in most models. Various inter-
actions were noted. In general, females had worse baseline
health status; baseline health status was worse in PR; patientsin PR were younger; younger patients had worse baseline
health status and GOLD classification; worse GOLD classifi-
cation patients had worse baseline health status. Proportion of
the variance of the MCIDs (R2) explained in these models was
between 0.205 and 0.405.4. Discussion
4.1. Main findings
The present study demonstrated first of all that MCID es-
timates for improvement on the CAT, CCQ, and SGRQ were
significantly three to seven times larger for COPD patients
with worse baseline health status than for those with better
baseline health status; however, they were much smaller
for deterioration. Second, MCID estimates proved to be
larger during intervention, in this case PR, compared with
RCP possibly due to baseline differences. Females, elderly,
COPD GOLD I and II patients, and patients with fewer co-
morbidities had overall larger MCID estimates for improve-
ment and smaller ones for deterioration compared with their
counter groupsdalthough not necessarily all significant.
Complex interactions between the variables were observed.4.2. Interpretation of outcomes
4.2.1. MCID estimates for CAT, CCQ, and SGRQ
Most MCID estimates for the CAT for improvement and
deterioration were between 61.50 and 63.50, which is in
Fig. 3. Box plots of theMCID estimates for both improvement and deterioration defined by low-baseline (meaning better) and high-baseline (meaning
worse) health status. Box plots of the MCID estimates for the CAT, CCQ, and SGRQ were grouped per health status baseline severity category. The left
graphs representMCID estimates for improvement, and the right half representMCID estimates for deterioration. The red horizontal line represents the
currently accepted fixedMCIDs from the literature (CAT2 points; CCQ0.40points; SGRQ4points). Abbreviations: CAT, COPDAssessment Test; CCQ,
Clinical COPDQuestionnaire; COPD, chronic obstructive pulmonary disease; MCID,minimal clinically important difference; SGRQ, St. George’s Res-
piratory Questionnaire.
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estimates for the CCQ were overall in the range of 60.30
and 60.60, which also matches previous studies
[40,43,44,48e52]. SGRQ MCID estimates ranged mostly
between four and nine points, which to some extent
matched existing evidence [40,43,44,53e57]. An estimate
of four points is generally accepted in interpreting the rele-
vance of clinical trial outcomes. This estimate derived
among others from patients treated with salmeterol in a
clinical trial, but also from PR and hospital admitted pa-
tients [53e56]. The present study confirms that this four-
point estimate could potentially be valid in RCP, but should
be larger for interventions.
4.2.2. Baseline health status
MCIDsmay be dependent on the initial baseline health state
of the patient [16,17,20,21,23e39,69]. It did significantly
impact ourMCIDestimates forCOPDhealth status tools.High-
er baseline scores (meaning worse) resulted in three to seven
times larger MCID estimates for improvement and four to six
times smaller estimates for deterioration compared with pa-
tients with a better baseline status. This means that these pa-
tients required a relative large reduction in symptoms and
burden of disease before they felt better, and only little deterio-
ration before they felt worse. Interaction between baseline
health status and other variables (gender, study setting, age,
and spirometry classification) was observed, potentially influ-
encing this observed MCID pattern.
Most authors recognize that patients with worse baseline
scores require more change before it is to be considered clin-
ically relevant simply because there is more room for change
[16,20,24,30,31,34e39]. Small improvements are not
considered important after intervention or during routine
clinical practice. On the other hand, only small progression
of their severe health status would be considered a relevant
deterioration. Although perhaps this may be considered a
predictable outcome, no former studies in COPD health sta-
tus have explored this phenomenon in MCID research.
Regression to the mean in our study may explain part of
the outcome. Other studies considered the use of relative
MCIDsddefined as change in percentage from baselinedto
solve the baseline dilemma [20,21,29,36,70]. Relative
MCID estimates in the present study were approximately
10% for improvement and þ20% for deterioration. This
could possibly be a solution and may be applied in clinical
practice to interpret individual change scores.
4.2.3. COPD disease severity
It has been hypothesized that disease severitydmeasured
in the present study by spirometrydcould impact the MCID
[16,17,20,23e39]. Previousdbut also presentdresearch
demonstrated that worse health status was correlated with
worse lung function [9e13], although this correlation was
only weak to moderate [4e7]. Worse GOLD-classified pa-
tients had also worse baseline health status in our study and
were in general younger. Our study suggested that MCIDestimates were larger for improvement and smaller for dete-
rioration in GOLD I/II patients compared with GOLD III/IV
patients. This pattern is vice versa the pattern found for the
impact of the baseline health status severity on the MCID.
Severity of health status is thus not equivalent to COPD dis-
ease severity, as expressed in the small-to-moderate correla-
tion between spirometry and health status. It could be argued
that patients with more severe lung function would experi-
ence more exacerbations and hospital admissions, which
could mean that small changes in the disease state could
already be considered important [33]. Age might have inter-
acted in the pattern observed.
4.2.4. Study setting
Setting may impact an instrument’s MCID [17,20,25,38],
potentially leading to larger MCIDs during intervention
[71]. In the present study, MCID estimates for improvement
and deterioration in COPD health status were indeed larger
during intervention in PR than RCP, although not all results
were significant. Patients experienced more change during
intervention as a result of treatment, leading to a larger MCID
estimate. This perhaps predictable result has not been demon-
strated in previous COPD health status research. A systematic
review by Alma et al. (2018) [40] on these MCIDs could not
observe a similar pattern. In RCP, smaller changes may be
noted and regarded relevant. In the present study, patients dur-
ing PR were significantly younger and had worse spirometry
and health status at baseline. These factors could have inter-
acted with the different MCID estimates between both set-
tings. The sole impact of setting on the MCID can therefore
not be quantified. Furthermore, the sample size during RCP
was much smaller, possibly impacting estimates too. Finally,
it remains unclear, whether this finding is specific for a reha-
bilitation intervention or is generally true for any kind of inter-
vention. For this question, further studies would be needed.
4.2.5. Gender, age, and comorbidities
Gender, age, and comorbidities could impact health status
[8e10,13e15].First, genderwashypothesized to impact health
status and its MCIDs [23]. Men and women evaluated health
status differently. Females paymore attention to dyspnea, emo-
tions, and anxiety; and they hadmore comorbidities [5,72]. The
present study demonstrated that females had (nonsignificant)
larger MCID estimates for improvement and smaller ones for
deterioration. Here, the worse baseline health status of females
could interact and explain our findings.
Next, age may possibly impact the MCID too [17,23].
Younger patients experienced significantly worse health
status and dyspnea compared with elderly [5,73]. However,
older age has also been associated with worse health status
[5,14]. In the present study, MCID estimates were larger for
improvement and smaller for deterioration in elderly,
although not all significant. Older patients had significantly
better baseline health status and spirometry. The study in
RCP included significantly more elderly than during PR.
However, the other interacting patterns found above cannot
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contradict the results by Arima et al. [22] that older patients
had lower/smaller MCIDs. These authors hypothesized that
elderly had lower expectations, being satisfied, and thus
requiring smaller MCIDs.
Finally, comorbidities could impact health status and its
MCIDs [17]. Patients with COPD experience a variety of co-
morbidities [74]. MCIDs for improvement were larger for
RCP patients with fewer comorbidities and smaller in deteri-
oration for this group. Comorbidities contribute to the overall
disease severity, which would match the pattern found for the
COPD disease severity defined by spirometry. Patients with
fewer comorbidities were significantly younger, which could
imply that age interacted in the pattern too.4.3. Strengths and limitations
The present study is the first study to explore the impact
of various factors on MCID estimates for COPD health sta-
tus tools. It used a large number of observations obtained
from two settings during different follow-up periods
applying both anchor- and distribution-based approaches.
Although the impact of study setting, intervention, and
baseline health status score was perhaps predictable, no
previous studies have confirmed this in COPD research.
No standard approach exists to evaluate the impact of fac-
tors on the MCID. The present study dichotomized the
impact factors into subgroups. This has been applied by
other authors in MCID research outside the field of COPD
[24,28,34,35,38,39,69]. The current authors summed up
and subsequently analyzed all health status change scores
simultaneously to allow for subgroup analysis. The depen-
dency of the change scores was only moderate. Alma et al.
[44] showed that the recall period was of limited influence
on the MCID, supporting the validity of combining all mea-
surements. Finally, the difference between MCID estimates
was tested and P-values were corrected for multiple testing.
There are, however, limitations too. Overall, the patterns
observed were not all significant after correcting for multi-
plicity. Owing to the exploratory nature of this study, we
chose to report general trends. Next, impact factors on
the MCID were analyzed individually; however, interac-
tions have been observed between the various factors. This
makes simple conclusions difficult to establish; especially
as the explained variance R2 was low. Furthermore, in the
anchor-based approach, the GRC was used to differentiate
between important and unimportant change. Although cor-
relations fulfilled the pre-set requirements [68], observed
correlations were considered weak to moderate. Moreover,
it has been argued that GRC estimates could be more
related with the follow-up health status score because of
a response shift, therefore not certainly representing change
from baseline [75]. Next, the division between PR and RCP
patients was unequal, therefore providing more weight to
PR measurements. GRC scoring patterns between PR and
RCP were also significantly different. Setting impactedthe MCID, possibly influencing other subgroup analyses
too. Finally, the study on comorbidities was only valid dur-
ing RCP, as scores were not readily available for PR.
4.4. Implications for clinical practice and future
research
At the group level, regression to the mean may play a ma-
jor role in clinical trials. This means that less weight will be
distributed to outlying measurements, balancing out extreme
scores. It could be hypothesized that this will minimize the
impact of individual patient-related factors and the health sta-
tus baseline score on the MCID. However, if samples have
extreme baseline characteristics or unbalanced divisions, sub-
group analyses with clustered MCIDs would be preferred to
interpret outcomes in scientific research more precise. The
specific trends found for the impact of factors on the MCIDs
of COPD health status tools in the present study might be a
start to develop an algorithm in evaluating individual health
status changes during clinical practice using tailored MCIDs.
More research would be required here to confirm our findings
and explore the interactive nature of the variables.5. Conclusions
The MCID is currently used as a nonadaptable param-
eter in the interpretation of COPD health status during clin-
ical trials. However, our study demonstrated that a complex
interaction of study setting, baseline health status, gender,
age, spirometry classification, and comorbidities potentially
impacted the MCID estimates for both improvement and
deterioration on three major health status questionnaires.
More accurate individual interpretation of outcomes in sci-
entific research and clinical practice would benefit from
developing and using possibly clustered or even tailored
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